Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017

Sun, Haifeng; Xue, Li; Guo, Ya-Huan; Du, Jianqiang; Kang, Nan; Li, Ming

doi:10.1080/07853890.2022.2039957

Cited by 18 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And these results correspond with a study conducted by (Murthy et al 2017), revealed that the prevalence of EBV-positive in DLCBL ranges from 2.5 to 14.0 %, with East Asians having a higher incidence and the majority of cases occur in patients over the age of 50, with a male predominance. Moreover, other study achieved by (Sun et al 2022) showed that males and females aged 50-69 had an age-standardized NHL incidence rate of 17.54 and 11.75 per 100,000 individuals, respectively. NHL was the most common type of malignant lymphoma for both males and females globally (from 81 % to 95 % of malignant lymphoma in males, and from 83 % to 96 % of malignant lymphoma in females (Saito and Matsuoka 2020;Alhasnawi and Aljanaby, 2022).…”

Section: Discussionmentioning

confidence: 89%

Epstein barr virus associated Hodgkin and non-Hodgkin lymphoma

Naser

Hassoon

2022

ijhs

View full text Add to dashboard Cite

Background: The Epstein-Barr virus (EBV) has been linked to a variety of B-cell lymphomas, including Burkitt lymphoma (BL), classical Hodgkin lymphoma (cHL), and diffuse large B-cell lymphoma (DLBCL), at rates ranging from 5 to 10% of DLBCL cases to >95% in endemic BL. Methods: The Present study conducted in AL-Najaf Holy City; it is a cross sectional study. All patients were recruited from Middle Euphrates Cancer Research Unit Laboratory, from pre-existing samples. Tissues collected from the previously mentioned laboratory were fixed in 10% formalin and placed in a cassette before being embedded in paraffine. The tissues were examined and diagnosed as with Hodgkin disease. Eighty samples were subjected in the present study. All study group was diagnosed formerly as paraffin imbedding blocks. Molecular analysis also used to detection of EBV-LMP-1 Gene. Histopathological examination using hematoxylin and eosine stain (H&E) then examining under light microscope to check for EBV-LMP-1 protein in twenty block samples of tissues with lymphoma. Results: The result of the current study revealed that EBV-LMP-1 marker found in 12.5% of cases that had been diagnosed by PCR and IHC.

show abstract

Section: Discussionmentioning

confidence: 89%

Epstein barr virus associated Hodgkin and non-Hodgkin lymphoma

Naser

Hassoon

2022

ijhs

View full text Add to dashboard Cite

show abstract

“…The incidence of NHL gradually increases in malignant lymphoma, accounting for about 90%, and the incidence increases with age, especially in males (Liu et al 2022). Conventional treatments for NHL include chemotherapy, radiotherapy, stem cell transplantation and targeted therapy, overall survival rate of NHL within 5 years was only 70% (Sun et al 2022). Rituximab was approved by the US FDA for the treatment of B-cell lymphoma, and the therapeutic effect of most patients has been signi cantly improved, but 30-45% of patients still suffering from relapse or progression (Wang and Li.…”

Section: Discussionmentioning

confidence: 99%

Study on the mechanism of Euscaphic acid in the treatment of non-Hodgkin lymphoma based on network pharmacology and molecular docking

li,

Liang,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) is a highly heterogenous disease. 5-year survival duration after diagnosis is poor among patients with aggressive/relapsing form of NHL. Our previous research found for the first time that Euscaphic acid (EA) has anti-tumor effects in NHL. However, the underlying mechanism by which EA plays a role in NHL remains unclear. In this study, we used network pharmacology and molecular docking to investigate the target and mechanism of the pharmacological action of EA on NHL. The EA-related targets and NHL-related targets were collected from the public database and overlapped to obtain the potential targets of EA-related anti-NHL. Target interaction was analyzed using STRING database, and 10 core target genes (TNF, PPARG, MMP9, HSP90AA1, PTGS2, IGF1R, AR, ESR2, NR3C1, MMP2) was screened by Cytoscape software. In the GO enrichment analysis and KEGG pathway analysis, TNF, PTGS2, PPARG and MMP9 are mainly enriched in the IL-17 signaling pathway, PPAR signaling pathway. The molecular docking results show there was strong interaction between the top 10 core targets and the EA. In addition, we found that EA inhibited the proliferation of RAJI NHL cells and induced cell apoptosis. These results suggested that EA may act on TNF, PTGS2, PPARG, and MMP9 through the IL-17 and PPAR signaling pathways, thereby exerting anti-NHL effects.

show abstract

“…Estimated annual percentage changes (EAPCs) of incidence rates were used to evaluate the incidence trends during 2010-2019. EAPC is a summarizing and widely used measure that assesses ASR trends over a specified time period (Hankey et al, 2000;Sun et al, 2022). Natural logarithm of regression line fitting rates were used; that is, y = a + βx + e, where y = ln (ASR) and x is the calendar year.…”

Section: Discussionmentioning

confidence: 99%

Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019

Qiang²,

Fang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: The study aimed to quantify the global trends of the incidence rates of multidrug-resistant (MDR) tuberculosis (MDR-TB) and extensively drug-resistant (XDR) tuberculosis (XDR-TB).Methods: Cases, age-standardized rates (ASRs), and incidence rates of MDR-TB and XDR-TB during 2010–2019 were obtained from the Global Burden of Disease Study 2019. The incidence trends of MDR-TB and XDR-TB were evaluated using the estimated annual percentage changes (EAPCs) in ASRs. The relationships among the ASRs of MDR-TB and XDR-TB, the MDR rate, the XDR rate, and socio-demographic index (SDI) were assessed using locally weighted regression and Pearson’s correlation coefficient.Results: The global ASR of MDR-TB on average decreased by 1.36% (EAPC = −1.36, 95% confidence interval [CI] = −2.19 to −0.52) per year whereas that of XDR-TB was stable (EAPC = 0.69, 95% CI = −0.15–1.54) during 2010–2019. The incidence trends of MDR-TB in most regions and countries were decreasing, but those of XDR-TB were increasing. People aged 35–44 and 55–64 years had the highest incidence rates for MDR-TB and XDR-TB. The MDR and XDR rates both peaked in those aged 35–44 years. Areas with higher SDI tended to have lower ASRs of MDR-TB (p < 0.001, ρ = −0.43).Conclusion: The current achievements for the incidence trends of MDR-TB and XDR-TB are insufficient. More strategies and tools need to be developed to further curb MDR-TB and XDR-TB, especially in high-risk areas and age groups, and in low SDI regions.

show abstract

Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017

Cited by 18 publications

References 37 publications

Epstein barr virus associated Hodgkin and non-Hodgkin lymphoma

Epstein barr virus associated Hodgkin and non-Hodgkin lymphoma

Study on the mechanism of Euscaphic acid in the treatment of non-Hodgkin lymphoma based on network pharmacology and molecular docking

Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019

Contact Info

Product

Resources

About